➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Johnson and Johnson

Last Updated: October 28, 2021

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 040195

Email this page to a colleague

« Back to Dashboard

NDA 040195 describes ACETAZOLAMIDE, which is a drug marketed by Accord Hlthcare, Alembic Pharms Ltd, Cadila, Heritage Pharma, Indicus Pharma, Micro Labs Ltd India, Mylan, Nostrum Labs Inc, Novast Labs, Alra, Appco, Ascot, Breckenridge, Eywa Pharma, Lannett, Mankind Pharma, Novitium Pharma, Rubicon, Strides Pharma, Sun Pharm Industries, Taro, Vangard, Watson Labs, Emcure Pharms Ltd, Hospira, Mylan Asi, Par Sterile Products, West-ward Pharms Int, Xgen Pharms, and Zydus Pharms, and is included in thirty-two NDAs. It is available from twenty-two suppliers. Additional details are available on the ACETAZOLAMIDE profile page.

The generic ingredient in ACETAZOLAMIDE is acetazolamide sodium. There are ten drug master file entries for this compound. Five suppliers are listed for this compound. Additional details are available on the acetazolamide sodium profile page.
Summary for 040195
Formulation / Manufacturing:see details
Pharmacology for NDA: 040195
Mechanism of ActionCarbonic Anhydrase Inhibitors
Medical Subject Heading (MeSH) Categories for 040195
Suppliers and Packaging for NDA: 040195
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
ACETAZOLAMIDE acetazolamide TABLET;ORAL 040195 ANDA A-S Medication Solutions 50090-0577 50090-0577-1 12 TABLET in 1 BOTTLE (50090-0577-1)
ACETAZOLAMIDE acetazolamide TABLET;ORAL 040195 ANDA Taro Pharmaceuticals U.S.A., Inc. 51672-4022 51672-4022-1 100 TABLET in 1 BOTTLE (51672-4022-1)

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrength125MG
Approval Date:May 28, 1997TE:ABRLD:No

Profile for product number 002

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrength250MG
Approval Date:May 28, 1997TE:ABRLD:No

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.